Abiraterone acetate — is only the second line palliative treatment?

Abstract

One of the most common malignancies in men is prostate cancer [1]. The radical treatment of locally advanced prostate cancer are used such methods as surgery — radical prostatectomy and radiotherapy [2]. The use of hormonal therapy and palliative chemotherapy can extend the time to disease progression (PFS, progression-free survival) and overall survival (OS). Palliative hormonal therapy allows for regression biochemical improvement in general condition and reduce the pain caused by cancer. The use of anti-androgens, and steroids rotation, resulting in prolonged time to progression of the disease. In castration resistant prostate cancer to standard practice after failure of docetaxel, possible and only in Poland, is now the use of abiraterone acetate in the second line palliative treatment [3, 4].

The paper presents two cases of man with prostate cancer in the abiraterone acetate was used in the second and fifth lines of therapy with a good therapeutic effect.